跳至主要内容
临床试验/NCT02481518
NCT02481518已完成4 期

Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity

Mahidol University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2015年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
30
试验地点
1
主要终点
Acute kidney injury

研究概览

简要总结

The purpose of this study is to determine whether magnesium preloading reduce incident of cisplatin induced acute kidney injury in head and neck cancer who receiving low dose cisplatin (40 mg/m2 weekly for 7 weeks).

详细描述

Randomized controlled trial comparing efficacy of magnesium preloading versus normal saline for prevention of acute and chronic nephrotoxicity of cisplatin.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 18 years
  • Eastern Cooperative Oncology Group score 0-2
  • First Diagnosed Head and neck cancer and plan for treatment with cisplatin
  • Serum creatinine ≤1.5 mg/dl or eGFR≥60(ml/min/1.73 m2)

排除标准

  • Prior treatment with cisplatin before randomization
  • Uncontrolled concurrent disease
  • Pregnancy

研究组 & 干预措施

Magnesium

Experimental

Magnesium preloading group : Magnesium preloading for Cisplatin treatment

干预措施: Magnesium (Drug)

Control

Active Comparator

Control group : Normal saline preloading for cisplatin treatment

干预措施: Control (Other)

结局指标

主要结局

Acute kidney injury

时间窗: 7 days after cisplatin administration

Comparing serum creatinine before Cisplatin treatment and seven days after cisplatin treatment

次要结局

  • Nephrotoxicity(up to 12 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验